医学
三尖瓣
单中心
反流(循环)
不利影响
内科学
心脏病学
阀门更换
外科
三尖瓣关闭不全
心脏瓣膜
狭窄
作者
Yiwei Wang,Mengen Zhai,Yu Mao,Tingting Yang,Guangyu Zhu,Yang Liu,Jian Yang
摘要
Abstract Background Functional tricuspid regurgitation (FTR) following left‐sided valve surgery (LSVS) is of clinical significance due to its high recurrence and mortality rates. Transcatheter therapy presents a potential solution to address this issue. Aims The study aimed to assess the safety and efficacy of transcatheter tricuspid valve replacement using the Lux‐Valve system in a single center for patients with FTR after LSVS. Methods From June 2020 to April 2023, 20 patients with symptomatic severe FTR after LSVS were referred to our center. A multidisciplinary cardiac team evaluated these patients for suitability for transcatheter tricuspid valve replacement with Lux‐Valve systems. Primary efficacy and safety endpoints were immediate postoperative tricuspid regurgitation severity ≤ moderate and major adverse events during follow‐up. Results Twenty patients (average age 65.7 ± 7.4 years; 65.0% women) successfully underwent Lux‐Valve system implantation after LSVS. All patients achieved ≤ moderate tricuspid regurgitation immediately after the procedure. Only one patient (5.0%) experienced a procedure‐related major adverse event, leading to in‐hospital mortality due to pulmonary infection. At the 6‐month follow‐up, 17 patients (89.5%) improved to New York Heart Association functional class I to II ( p < 0.001). The overall Kansas City Cardiomyopathy Questionnaire score significantly improved (35.9 ± 6.7 points to 58.9 ± 5.8 points, p < 0.001). Conclusion The Lux‐Valve system was found to be safe and effective for treating FTR after LSVS. It resulted in positive early outcomes, including a significant reduction in FTR, improved functional status, and enhanced quality of life, especially in high‐risk patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI